Ipamorelin legal record and study references

FDA approval

Ipamorelin is not FDA-approved for any indication. It has no approved therapeutic use from the FDA, EMA or another regulatory authority. The published Phase 2 bowel-resection trial missed its primary endpoint.

The FDA compounding entries

On FDA's page current as of April 22, 2026, titled Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, Ipamorelin acetate appears in Category 2 under the 503B interim policy, with an entry dated September 29, 2023. It also appears in the separate table of bulk substances nominated but withdrawn, with safety concerns retained. FDA publishes no withdrawal date.

FDA evaluated both Ipamorelin free base and Ipamorelin acetate for the October 29, 2024 Pharmacy Compounding Advisory Committee. The committee voted 0 yes, 12 no and 1 abstention against adding each form to the 503A Bulks List. As of October 1, 2026, FDA had published no rule, and neither form was on the 503A Bulks List or the 503B Bulks List.

A favorable account based on the withdrawn nomination would leave me unconvinced. The dated entries describe different actions under different frameworks. A nomination's withdrawal supplies no approval or clearance. This account of the public record cannot decide the lawfulness of an individual situation.

WADA and laboratory detection

Ipamorelin is prohibited in sport at all times under WADA category S2. The analytical papers establish urine-testing methods, which address identification rather than medical efficacy. The sports prohibition and the drug-approval question each stand on their own terms.

Ipamorelin reference standard

A laboratory reference standard supplies comparison material for analytical measurement or identification. It addresses the substance being measured. It supplies no human treatment indication. The 2011 method paper is a useful starting point for this analytical use of the word reference.

Starting points

For detection, begin with Thomas and colleagues' urine assays and the Timms method. For human exposure, begin with Gobburu; for the postoperative outcome, Beck. Raun supplies the founding selectivity experiments. Lall supplies an awkward mouse result for any sweeping fat-loss claim.

The list also includes related compounds. GSK894281 supplied the rat cardiovascular warning, NN703 was the modified oral compound, and the Bowers study tested GHRP-2 with GHRH. Their names are consequential to the conclusions.